Prostatype Genomics AB's EBIT per Share for the
six
months ended in Dec. 2025 was kr-0.37.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr-1.78.
During the past 3 years, the average EBIT per Share Growth Rate was 85.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 76.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Prostatype Genomics AB's EBIT per Share or its related term are showing as below:
OSTO:PROGEN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -94.8 Med: 83.95 Max: 93.4
Current: 85.7
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Prostatype Genomics AB was 93.40% per year. The lowest was -94.80% per year. And the median was 83.95% per year.
OSTO:PROGEN's 3-Year EBIT Growth Rate is ranked better than 95.27% of 169
companies
in the Medical Diagnostics & Research industry
Industry Median: 13
vs OSTO:PROGEN: 85.70
Prostatype Genomics AB (OSTO:PROGEN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Prostatype Genomics AB EBIT per Share Related Terms
Prostatype Genomics AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-1.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a EBIT per Share of kr-1.78 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #8 out of 169 companies in the Medical Diagnostics & Research industry, placing it in the top 4.7%.
Is Prostatype Genomics AB's EBIT per Share too high?
Prostatype Genomics AB's current EBIT per Share is kr-1.78. Based on the distribution chart, Prostatype Genomics AB ranks #8 out of 169 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #8 out of 169 companies for EBIT per Share. This places Prostatype Genomics AB in the top 5% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.00, based on 169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current EBIT per Share is kr-1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.33 — trading 200% above its estimated fair value. The current EBIT per Share is kr-1.78. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current EBIT per Share is kr-1.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.33 is trading 200% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
EBIT per Share: kr-1.78
GF Value™: kr0.11 vs. price of kr0.33 (200% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
